Английская Википедия:Bebtelovimab
Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug
Bebtelovimab is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19.[1][2][3][4]
Possible side effects include itching, rash, infusion-related reactions, nausea and vomiting.[1]
Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death.[1] Bebtelovimab is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.[5]
Шаблон:As of, bebtelovimab is not authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.[6]
Medical uses
Bebtelovimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022,[1] and revoked it in November 2022.[6] The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in people aged 12 years of age and older weighing at least Шаблон:Convert with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.[1]
Bebtelovimab is not authorized for people who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19.[1] Treatment with bebtelovimab has not been studied in people hospitalized due to COVID-19.[1]
Bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.[7]
History
Bebtelovimab emerged from a collaboration between Eli Lilly and AbCellera.[2] Bebtelovimab was discovered by AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.[2][3]
Society and culture
Legal status
Bebtelovimab was authorized for medical use in the United States via an emergency use authorization in February 2022.[1][8][9][10]
Шаблон:As of, bebtelovimab is not authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.[6][9] Eli Lilly and its authorized distributors have paused commercial distribution of bebtelovimab until further notice by the U.S. Food and Drug Administration (FDA).[6]
Names
Bebtelovimab is the proposed international nonproprietary name (pINN).[11]
References
External links
Шаблон:Monoclonals for infectious disease and toxins Шаблон:Eli Lilly and Company Шаблон:Portal bar Шаблон:Antiinfective-drug-stub
- ↑ 1,0 1,1 1,2 1,3 1,4 1,5 1,6 1,7 Шаблон:Cite press release Шаблон:PD-notice
- ↑ 2,0 2,1 2,2 Шаблон:Cite press release
- ↑ 3,0 3,1 Шаблон:Cite press release
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite web Шаблон:PD-notice
- ↑ 6,0 6,1 6,2 6,3 Шаблон:Cite web Шаблон:PD-notice
- ↑ Шаблон:Cite web Шаблон:PD-notice
- ↑ Шаблон:Cite web
- ↑ 9,0 9,1 Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite journal
